Welcome to the Q3 2024 Earnings Call Transcript by Eisai Co., Ltd.
Company Participants:
Haruo Naito
Representative Corporate Officer & CEO
Terushige Iike
Executive Vice President, Chief Strategy and Planning Officer
Katsuya Haruna
Group Officer & Executive Vice President, U.S. Business Operations
Kazuhiko Tamura
Vice President, Eisai Demand Chain Systems
Lynn Kramer
Vice President, Chief Clinical Officer
Takashi Owa
Senior Vice President Chief Scientific Officer Japan Medical Safety
Tomo Ogawa
Department Manager, Clinical Operations
Conference Call Participants:
Hidemaru Yamaguchi – Citigroup
Seiji Wakao – JPMorgan
Takashi Akahane – Tokai Tokyo
Miki Sogi – Bernstein
Shinichiro Muraoka – Morgan Stanley
Kazuaki Hashiguchi – Daiwa Securities
Hinako Banno – Nikkei Newspaper
Yuki Osanai – Yomiuri Shimbun
Operator:
Thank you very much for taking your time out of your busy schedule to attend the Financial Results and Business Update Presentation for Q3 Fiscal 2024 by Eisai Company Limited.
Today, we are pleased to share with you our Q3 2024 earnings call transcript where we will discuss our financial results and provide a business update. Our team of executives, led by our CEO Haruo Naito, will delve into the key highlights of the quarter and shed light on our future strategies.
During this call, we will address the performance of our U.S. business operations, our demand chain systems, clinical operations, and medical safety initiatives in Japan. Additionally, our Chief Scientific Officer will provide insights into our research and development efforts.
We are also honored to have esteemed participants from leading financial institutions and media outlets joining us today. Your presence and engagement are greatly appreciated as we share our progress and outlook for the future.
At Eisai, we remain committed to advancing innovative healthcare solutions that make a difference in the lives of patients globally. We thank you for your continued support and look forward to a productive discussion during this call.
Impact on Me:
As a stakeholder or investor in Eisai Co., Ltd., the insights shared during the Q3 2024 earnings call transcript can provide valuable information on the company’s performance, growth strategies, and future prospects. This can help me make informed decisions regarding my investment portfolio and assess the potential impact on my financial goals.
Impact on the World:
Eisai Co., Ltd.’s financial results and business update have the potential to influence the healthcare industry globally. The company’s innovative solutions and research efforts in areas such as clinical operations and medical safety in Japan can contribute to advancements in patient care and treatment outcomes worldwide. As Eisai continues to drive progress in healthcare, the ripple effects of its initiatives can be felt on a global scale.
Conclusion:
In conclusion, the Q3 2024 earnings call transcript by Eisai Co., Ltd. sheds light on the company’s performance, strategic direction, and impact on stakeholders. As Eisai remains at the forefront of healthcare innovation, the insights shared during this call have the potential to shape the future of the industry and benefit patients around the world. We look forward to the continued success and growth of Eisai as it continues its mission to improve human health.
